周二盘中，生物科技公司Krystal Biotech Inc.（KRYS）股价大幅下跌14.64%，主要原因是公司公布的季度业绩未能达到分析师预期。
根据公司最新财报，截至3月31日的季度调整后每股收益为1.20美元，虽然较去年同期的0.03美元有显著增长，但低于分析师平均预期的1.37美元。公司季度营收为8818万美元，同比增长94.9%，但仍未达到分析师预期的9624万美元。这一业绩miss可能是引发投资者抛售的主要原因。
尽管本季度业绩未达预期，但Krystal Biotech的整体表现仍显示出强劲的增长势头。公司报告的季度净收入达到3573万美元，相比去年同期有显著提升。值得注意的是，尽管股价出现大幅下跌，分析师对公司前景仍保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，12个月目标价中位数为215.00美元。这表明市场对Krystal Biotech的长期发展前景仍持积极看法，但短期内业绩波动可能会影响投资者信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.